Marsha earned her Masters and Ph.D in Molecular Genetics from Albert Einstein College of Medicine. Her thesis research was focused on developing gene therapy vectors for the treatment of inherited metabolic liver disorders and examining the genetics of the neurological movement disorder, Dystonia. She earned her Bachelor's degree in Biology at City College of the City University of New York where she began her career in the biomedical sciences as a research assistant. At City College, Marsha's research involved understanding how the anti-cancer drug, bleomycin, mediated tumor cell-death.
Dr. Caton has built her career in drug development having worked for some of the largest and most well-known Pharmaceutical Companies in the industry. She currently works as a Principal Scientist in Immuno-oncology, where she leads drug-approval submission regulatory writing teams. Her work involves evaluation of the efficacy, safety and tolerability of new drug entities for the treatment of various cancers.
Her professional interests include highlighting the importance of clinical research in discovering cures for debilitating diseases, particularly for patients with cancer. She is also very passionate about exposing girls to the biomedical sciences at an early age.